Cost-effectiveness of Intensive vs Standard Blood Pressure Control Among Older Patients With Hypertension
暂无分享,去创建一个
J. Melgarejo | Li Sun | H. Toh | Chun-Ting Yang | C. Liao | D. Wei | Zhenyu Zhang | Angie Hu
[1] V. Cornelius,et al. Time to Clinical Benefit of Intensive Blood Pressure Lowering in Patients 60 Years and Older With Hypertension , 2022, JAMA internal medicine.
[2] Weili Zhang,et al. Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension. , 2021, The New England journal of medicine.
[3] J. Danesh,et al. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. , 2021, European heart journal.
[4] C. Bulpitt,et al. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. , 2021, European heart journal.
[5] Duolao Wang,et al. Applicability and cost-effectiveness of the Systolic Blood Pressure Intervention Trial (SPRINT) in the Chinese population: A cost-effectiveness modeling study , 2021, PLoS medicine.
[6] Xu Yang,et al. Changing Paradigm for Vertigo/Dizziness Patients: a Retrospective Before-After Study from Tertiary Hospitals in Northwestern China , 2021, Journal of General Internal Medicine.
[7] G. Lip,et al. Atrial Fibrillation in the United Kingdom: Predicting Costs of an Emerging Epidemic Recognising and Forecasting the Cost Drivers of Atrial Fibrillation-related costs. , 2020, European heart journal. Quality of care & clinical outcomes.
[8] R. McManus,et al. Cost-Effectiveness of Initiating Pharmacological Treatment in Stage One Hypertension Based on 10-Year Cardiovascular Disease Risk , 2020, Hypertension.
[9] Shunping Li,et al. Applying SF-6D to measure health state utilities among the middle and old aged patients with hypertension in China , 2020, Health and Quality of Life Outcomes.
[10] Xiangli Cui,et al. Cost‐effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in China , 2020, BMC Health Services Research.
[11] D. King,et al. Estimated societal costs of stroke in the UK based on a discrete event simulation , 2019, Age and ageing.
[12] M. Burnier,et al. Adherence in Hypertension. , 2019, Circulation research.
[13] Q. Hua,et al. 2019 Chinese guideline for the management of hypertension in the elderly , 2019, Journal of geriatric cardiology : JGC.
[14] Mohammad Hosein Farzaei,et al. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2018, Lancet.
[15] G. Lip,et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. , 2018, European heart journal.
[16] D. Siscovick,et al. Cost-effectiveness analysis of intensive hypertension control in China. , 2018, Preventive medicine.
[17] Jackson T. Wright,et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2018, Journal of the American College of Cardiology.
[18] P. Ludman,et al. Clinical outcomes and costs of cardiac revascularisation in England and New York state , 2018, Open Heart.
[19] C. O’Seaghdha,et al. Cost-Effectiveness of Intensive versus Standard Blood-Pressure Control. , 2017, The New England journal of medicine.
[20] James R. Powell,et al. Cost‐Effectiveness of Intensive versus Standard Blood‐Pressure Control , 2017 .
[21] Nicolas R. Ziebarth,et al. End-Of-Life Medical Spending In Last Twelve Months Of Life Is Lower Than Previously Reported. , 2017, Health affairs.
[22] T. Wilt,et al. Pharmacologic Treatment of Hypertension in Adults Aged 60 Years or Older to Higher Versus Lower Blood Pressure Targets: A Clinical Practice Guideline From the American College of Physicians and the American Academy of Family Physicians , 2017, Annals of Internal Medicine.
[23] A. Schuler,et al. Cost-effectiveness of Intensive Blood Pressure Management. , 2016, JAMA cardiology.
[24] Xueli Yang,et al. Predicting the 10-Year Risks of Atherosclerotic Cardiovascular Disease in Chinese Population: The China-PAR Project (Prediction for ASCVD Risk in China) , 2016, Circulation.
[25] T. Trikalinos,et al. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. , 2016, JAMA.
[26] Jackson T. Wright,et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. , 2016, The New England journal of medicine.
[27] Jiang He,et al. Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. , 2015, Circulation.
[28] Rosanne Raso,et al. Changing a paradigm. , 2015, Nursing management.
[29] R. Burge,et al. Inpatient cost of treating osteoporotic fractures in mainland China: a descriptive analysis , 2015, ClinicoEconomics and outcomes research : CEOR.
[30] Jennifer G. Robinson,et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.
[31] D. Newman-Toker,et al. Rising annual costs of dizziness presentations to U.S. emergency departments. , 2013, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.
[32] D. Malone,et al. Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation , 2013, Stroke.
[33] Shanlian Hu,et al. Economic Burden of Individual Suffering from Atrial Fibrillation-Related Stroke in China. , 2013, Value in health regional issues.
[34] A. Bower,et al. The direct and indirect costs of long bone fractures in a working age US population , 2013, Journal of medical economics.
[35] J. Brazier,et al. Using health state utility values from the general population to approximate baselines in decision analytic models when condition-specific data are not available. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[36] H. Jin,et al. Cost-effectiveness of diagnostic approaches to vasovagal syncope. , 2010, Chinese medical journal.
[37] Yi Fang,et al. Acute Kidney Injury in a Chinese Hospitalized Population , 2010, Blood Purification.
[38] Li Yang,et al. Economic burden of cardiovascular diseases in China , 2008, Expert review of pharmacoeconomics & outcomes research.
[39] M. Palta,et al. US Norms for Six Generic Health-Related Quality-of-Life Indexes From the National Health Measurement Study , 2007, Medical care.
[40] Patrick W. Sullivan,et al. Preference-Based EQ-5D Index Scores for Chronic Conditions in the United States , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.
[41] Paul C Nagle,et al. Review of recent US cost estimates of revascularization. , 2004, The American journal of managed care.
[42] Antonio Addis,et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. , 2002, Clinical therapeutics.
[43] M. Marcus,et al. The heart in hypertension. , 1992, The New England journal of medicine.
[44] R. C. C. Coutinho. Quality of life of patients with hypertension , 2012 .